EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis

Gerald F Watts, Christie M Ballantyne, Agustin Blanco Echevarria, Jamie Smith, Robert S Rosenson, Savitha Subramanian, James Trippi, Norman Lepor, Archna Bajaj, Vladimir Blaha, Russell Scott, Alexis Baass und 11 weitere

New England Journal of Medicine · 05.11.2026 · 395 (18) · 1805-1817

DOI: 10.1056/nejmoa2610014 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 05.11.2026. Verfasst von Gerald F Watts und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Western Australia and Department of Cardiology, Royal Perth Hospital, Perth. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, Pancreatitis, RNA, Small Interfering. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIHypertriglyceridemiaPancreatitisRNA, Small InterferingTriglyceridesAdultFemaleHumansMaleMiddle AgedCholesterolDouble-Blind MethodSeverity of Illness IndexAgedTreatment OutcomeFollow-Up StudiesIncidence

Substanzen

Apolipoprotein C-IIICholesterolplozasiranRNA, Small InterferingTriglycerides

Autor:innen und Institutionen

  • University of Western Australia and Department of Cardiology, Royal Perth Hospital, Perth.
  • Baylor College of Medicine and the Texas Heart Institute, Houston.
  • Hospital Universitario 12 de Octubre, Madrid.
  • Torbay and South Devon NHS Foundation Trust-Torbay Hospital (Department of Diabetes and Endocrinology), Torquay, United Kingdom.
  • Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine, Mount Sinai, New York.
  • University of Washington, Seattle.

Förderung

  • Arrowhead Pharmaceuticals

Zitieren

APA

Watts, G. F., Ballantyne, C. M., Blanco Echevarria, A., Smith, J., Rosenson, R. S., Subramanian, S., Trippi, J., Lepor, N., Bajaj, A., Blaha, V., Scott, R., Baass, A., Goldberg, I. J., Gallo, A., Diaz, J. L., Saxena, M., Li, J., Zhou, R., Aiyer, L., …, & SHASTA-3 and SHASTA-4 Study Groups (2026). Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis. New England Journal of Medicine, 395(18), 1805-1817. https://doi.org/10.1056/nejmoa2610014

Vancouver

Watts GF, Ballantyne CM, Blanco Echevarria A, Smith J, Rosenson RS, Subramanian S, et al. Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis. New England Journal of Medicine. 2026;395(18):1805-1817. doi:10.1056/nejmoa2610014

BibTeX
@article{Watts2026,
  author = {Watts, Gerald F and Ballantyne, Christie M and Blanco Echevarria, Agustin and Smith, Jamie and Rosenson, Robert S and Subramanian, Savitha and Trippi, James and Lepor, Norman and Bajaj, Archna and Blaha, Vladimir and Scott, Russell and Baass, Alexis and Goldberg, Ira J and Gallo, Antonio and Diaz, Jose Luis and Saxena, Manish and Li, Jianping and Zhou, Rong and Aiyer, Lalitha and Hellawell, Jennifer and Hamilton, James and Gaudet, Daniel and SHASTA-3 and SHASTA-4 Study Groups, SHASTA-3 and SHASTA-4 Study Groups},
  title = {Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {18},
  pages = {1805--1817},
  doi = {10.1056/nejmoa2610014}
}
Kostenlos starten →